Graft-versus-host disease overview

Jump to navigation Jump to search

Graft-versus-host disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Graft-versus-host disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Graft-versus-host disease overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Graft-versus-host disease overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Graft-versus-host disease overview

CDC on Graft-versus-host disease overview

Graft-versus-host disease overview in the news

Blogs on Graft-versus-host disease overview

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Graft-versus-host disease overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack. It occurs in 4-70% of patients undergoing stem cell transplant.[1] Acute GvHD typically occurs within 100 days of transplant. Chronic GvHD occurs after 100 days from transplant.[2] Nearly 40% of paitents will develop some form of GvHD.[2]

Historical Perspective

Classification

The classification of GvHD is based on bother severity and time of onset. The severity is based upon the stage and grade. The conglomeration of stages of GvHD of each organ affected gives the grade. Each affected organ has a staging system (stages 1-4), depending on the degree of organ dysfunction. The time of onset determines whether GvHD is acute or chronic. Acute GvHD occurs within the first 100 days of stem cell transplant. Chronic GvHD occurs after 100 days from transplant.

Pathophysiology

The pathophysiology of GvHD involves immune activation of donor-derived T cells, which mount a response against host tissue, especially the liver, skin, and GI tract. Antigen-presenting cells (APCs) are key players in the initiation of the process. Immune activation leads to inflammation and organ destruction.

Causes

The cause of GvHD is stem cell transplantation from an allogeneic donor.[2]

Differentiating GvHD from Other Diseases

Other possible etiologies for liver dysfunction in a patient who received stem cell transplant include CMV hepatitis and veno-occlusive disease. It is important to differentiate these etiologies from GvHD, as the treatment implications are different.

Epidemiology and Demographics

GvHD can occur in any population. Certain subsets of donor cells are less likely to result in GvHD, such as umbilical cord blood-derived stem cells, which contain fewer T cells than other sources of stem cells. There are no known racial disparities for GvHD. There are no particular geographic areas that are more prone to GvHD.

Risk Factors

One risk factor for GvHD is HLA-mismatched donor source. The greater the degree of mismatch, the greater the likelihood for GvHD.

Screening

There is no role for screening (secondary prevention) for GvHD. However, there is a significant role for primary prevention in GvHD. Such primary prevention measures include medications like methotrexate and antibiotics like ciprofloxacin for gut decontamination.

Natural History, Complications, and Prognosis

Natural History

Complications

The complications of GvHD stem from the resultant end-organ damage that occurs from immune activation. Complications include debilitating GI symptoms (including life-threatening diarrhea and abdominal pain), disruption of the GI mucosa and subsequent bacterial translocation and sepsis, liver failure, and skin infections.

Prognosis

The prognosis of GvHD is variable based on the severity of disease. Steroid-refractory GvHD has a much poorer prognosis then steroid-responsive GvHD.

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

References

  1. Al-Chaqmaqchi H, Sadeghi B, Abedi-Valugerdi M, Al-Hashmi S, Fares M, Kuiper R; et al. (2013). "The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease". PLoS One. 8 (4): e60367. doi:10.1371/journal.pone.0060367. PMC 3617218. PMID 23593203.
  2. 2.0 2.1 2.2 Meyer EH, Hsu AR, Liliental J, Löhr A, Florek M, Zehnder JL; et al. (2013). "A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease". Blood. 121 (24): 4955–62. doi:10.1182/blood-2013-03-489757. PMC 3682344. PMID 23652802.

Template:WS Template:WH